Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03978117 · ClinicalTrials.gov registry record · Phase 2

Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens

A Phase 2 study of Healthy, sponsored by Masonic Cancer Center, University of Minnesota.

Completed
Registry status
Phase 2
Development phase
300
Enrollment target
1
Study location

NCT03978117: Completed Phase 2 study of Healthy, sponsored by Masonic Cancer Center, University of Minnesota.

NCT03978117 is a Phase 2 study of Healthy that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 300 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03978117, a Phase 2 study of Healthy, has completed, sponsored by Masonic Cancer Center, University of Minnesota.

COMPLETED
Registry status
Phase 2
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

The goal of this research is to determine if consuming one of two study drinks will help enhance the detoxification of multiple environmental toxicants and cancer causing agents, particularly in subjects who are null for glutathione-S-transferase M1 (GSTM1), glutathione-S-transferase T1 (GSTT1), or both. If our research supports this idea, this drink could be an inexpensive dietary component, which could promote good health.

Primary Outcome

Carcinogen detoxification metabolites in urine. Biomarkers to be analyzed: 2-cyanoethyl mercapturic acid (CEMA), 3-hydroxypropyl mercapturic acid (HPMA1), 2-hydroxypropyl mercapturic acid (HPMA2), phenyl mercapturic acid (SPMA), 3-hydroxy-1-methylpropyl mercapturic acid (HMPMA1), 3-hydroxy-2-methylpropyl mercapturic acid (HMPMA2), and 3-hydroxy-3-methylpropyl mercapturic acid (HMPMA3),

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Freeze Dried Watercress Preparation
  • DIETARY_SUPPLEMENT Placebo Preparation

Study Locations (1)

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2021-02-18
Est. Completion 2024-11-13
Phase Phase 2

What the finished NCT03978117 record still lists

NCT03978117 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (54% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Freeze Dried Watercress Preparation is the first listed.

NCT03978117 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT03978117 about?

NCT03978117 is a clinical study titled "Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens". The goal of this research is to determine if consuming one of two study drinks will help enhance the detoxification of multiple environmental toxicants and cancer causing agents, particularly in subjects who are null for glutathione-S-transferase M1 (GSTM1), glutathione-S-transferase T1 (GSTT1), or ...

What is the current status of trial NCT03978117?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2021-02-18. Estimated completion is 2024-11-13.

What conditions does trial NCT03978117 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT03978117?

The interventions under investigation include: Freeze Dried Watercress Preparation (DIETARY_SUPPLEMENT), Placebo Preparation (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03978117?

This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03978117 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03978117's enrollment target sits among peer trials

300 77th of 1090 higher than 1,004 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03978117, the US trial registry maintained by the National Library of Medicine. NCT03978117 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.